文献速递头颈部肿瘤放疗放疗物理与技术

剂量与剂量平均LET对碳离子放疗后口咽黏膜毒性的影响

Impact of dose and dose-averaged linear energy transfer on oro-pharyngeal-mucosal toxicity in patients with non-squamous head and neck cancers treated with carbon-ion radiotherapy.
PubMed 文献 · Radiother Oncol · 2025-11-28

本研究评估51例非鳞状头颈部肿瘤患者碳离子放疗计划与临床结局,发现口咽黏膜受照剂量>70 Gy可预测晚期G3口窦瘘(OAF)发生,且中高剂量合并高LETd时风险更高;采用黏膜保护策略可降低黏膜剂量并维持局部控制。

要点

  • 口咽黏膜DRBE>70 Gy可预测碳离子放疗后晚期G3 OAF。
  • 中高剂量合并LETd≥75 keV/µm时OAF风险显著升高(2年无OAF生存38% vs 100%)。
  • 黏膜保护策略可降低黏膜剂量至<70 Gy并维持局部控制。

核心结论

  • 除黏膜保护策略外,优化口咽黏膜的DLV参数(61 Gy≤DRBE≤70 Gy、LETd≥50 keV/µm及体积)可能是预防碳离子放疗后晚期G3 OAF的有前景策略。

研究设计与样本

  • 评估51例非鳞状头颈部肿瘤患者的碳离子放疗计划并与临床结局相关,处方DRBE为68.8 Gy(65.6-76.8)/16次,采用LEM-I优化,前21例后采用黏膜保护策略(MS-CIRT)。

主要发现

  • 中位随访23个月,7例发生晚期G3 OAF,其中2例采用MS-CIRT。
  • 口咽黏膜DRBE>70 Gy可预测OAF发生。
  • 当>1 cm3黏膜保护区内DRBE|mMKM≥63 Gy且LETd≥75 keV/µm时,2年无OAF生存概率为38%,未超过阈值者为100%(p<0.001)。
  • 鼻窦原发和HD-CTV≥100 cm3也影响OAF发生。

关键数值与推荐

  • 黏膜保护策略采用DRBE约束(DRBE|0.1cm3<70 Gy)并维持靶区覆盖。
  • DLV参数定义:61 Gy≤DRBE≤70 Gy、LETd≥50 keV/µm及体积。
  • 关键阈值:DRBE|mMKM≥63 Gy且LETd≥75 keV/µm对应2年无OAF生存38% vs 100%(p<0.001)。

临床怎么用

  • 碳离子放疗非鳞状头颈部肿瘤时,应关注口咽黏膜DRBE和LETd分布,采用黏膜保护策略并优化DLV参数以降低晚期G3 OAF风险。

局限性

  • MS-CIRT的局部控制结果为有限数量患者的初步结果;样本量有限(51例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In head and neck carbon-ion radiotherapy (CIRT), high dose-averaged LET (LETd) and relative biological effectiveness weighted dose (DRBE) often overlap the oro-pharyngeal-mucosa (mucosa of oral cavity, oro-pharynx, nasopharynx, pharynx) beyond the target, resulting in serious complications. We investigated clinical and dosimetric predictors for late severe mucosal-toxicity/ oro-antral fistula (OAF) post-CIRT. MATERIALS AND METHODS: CIRT plans for 51 patients with non-squamous head and neck cancers (NSHNCs) were evaluated and correlated with clinical outcome. Prescription was DRBE of 68.8 Gy (65.6-76.8)/16 fractions optimized using Local Effect Model-I (LEM-I). After the first 21 patients a mucosa-sparing approach (MS-CIRT) was adopted, delineating healthy mucosa-to-spare within the high-dose PTV and applying DRBE constraints (DRBE|0.1cm3 < 70 Gy), maintaining target coverage. For the present analysis, DRBE was recomputed also with the modified microdosimetric kinetic model (mMKM) and LETd was calculated. Several clinical and dosimetric parameters including DLV-parameters (61 Gy ≤ DRBE ≤ 70 Gy, LETd ≥ 50 keV/µm, volume) that may be predictors of OAF were analyzed. RESULTS: MS-CIRT reduced mucosal doses to < 70 Gy, preserving local control (preliminary results in limited number of patients). Seven patients developed late G3 OAF after median follow-up of 23 months, including 2 with MS-CIRT. Doses to oro-pharyngeal mucosa > 70 Gy were predictive of OAF development. Even moderate-high doses correlated with OAF if they coincided with high-LETd. For instance, when more than 1 cm3 of mucosa-to-spare was exposed to DRBE|mMKM ≥ 63 Gy and LETd ≥ 75 keV/µm, 2-yr OAF-free survival probability was 38 % versus 100 % in cases where these thresholds were not exceeded (p < 0.001). Sino-nasal primary and HD-CTV ≥ 100 cm3 also influenced OAF development. CONCLUSION: Besides MS-CIRT strategy, optimizing DLV-parameters for oro-pharyngeal-mucosa may be a promising strategy in preventing late G3 OAF post-CIRT.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Nachankar A, Gora J, Schafasand M, et al. Impact of dose and dose-averaged linear energy transfer on oro-pharyngeal-mucosal toxicity in patients with non-squamous head and neck cancers treated with carbon-ion radiotherapy. Radiother Oncol. 2025. PMID: 41318000. doi:10.1016/j.radonc.2025.111314

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。